Rabies virus vaccines: is there a need for a pan-lyssavirus vaccine?
All members of the lyssavirus genus are capable of causing disease that invariably results in death following the development of clinical symptoms. The recent detection of several novel lyssavirus species across the globe, in different animal species, has demonstrated that the lyssavirus genus contains a greater degree of genetic and antigenic variation than previously suspected. The divergence of species within the genus has led to a differentiation of lyssavirus isolates based on both antigenic and genetic data into two, and potentially a third phylogroup. Critically, from both a human and animal health perspective, current rabies vaccines appear able to protect against lyssaviruses classified within phylogroup I. However no protection is afforded against phylogroup II viruses or other more divergent viruses. Here we review current knowledge regarding the diversity and antigenicity of the lyssavirus glycoprotein. We review the degree of cross protection afforded by rabies vaccines, the genetic and antigenic divergence of the lyssaviruses and potential mechanisms for the development of novel lyssavirus vaccines for use in areas where divergent lyssaviruses are known to circulate, as well as for use by those at occupational risk from these pathogens.
Animal Health and Veterinary Laboratories Agency, Weybridge, Surrey, KT15 3NB, United Kingdom.
Jennifer S
JS
Evans
Daniel L
DL
Horton
Andrew J
AJ
Easton
Anthony R
AR
Fooks
Ashley C
AC
Banyard
D000818:Animals; D014644:Genetic Variation; D006801:Humans; D011818:Rabies / Q000517:prevention & control* / Q000662:veterinary* / Q000821:virology; D011819:Rabies Vaccines / Q000276:immunology*; D011820:Rabies virus / Q000145:classification / Q000235:genetics* / Q000276:immunology*
D011819:Rabies Vaccines